Vir Biotechnology Inc (VIR)

Return on equity (ROE)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	-521,960	-615,061	515,837	528,584	-298,665
Total stockholders’ equity	US$ in thousands	1,150,380	1,590,240	2,077,960	1,431,850	716,852
ROE		-45.37%	-38.68%	24.82%	36.92%	-41.66%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-521,960K ÷ $1,150,380K
= -45.37%

Based on the provided data, Vir Biotechnology Inc's return on equity (ROE) has experienced significant fluctuations over the years.

In 2020, the ROE was notably negative at -41.66%, indicating that the company had a net loss relative to its shareholders' equity. This negative ROE suggests inefficiency in generating earnings from the shareholder's investments.

However, by the end of 2021, the ROE had substantially improved to 36.92%, reflecting a positive turnaround in the company's profitability and efficiency in utilizing its equity to generate returns.

In 2022, the ROE remained positive at 24.82%, indicating continued profitability and improved performance in leveraging shareholder equity.

By the end of 2023, the ROE declined sharply to -38.68%, signifying a reversal in performance and a decrease in profitability relative to the shareholders' equity.

Most recently, in 2024, the ROE further decreased to -45.37%, highlighting a significant decline in the company's ability to generate profits compared to the shareholders' equity.

Overall, the fluctuating trend in Vir Biotechnology Inc's ROE suggests varying levels of profitability and efficiency in utilizing equity over the years, with periods of improvement followed by declines in performance. Further examination of the company's financial strategies and operational performance would be necessary to understand the underlying factors driving these changes in ROE.